ANDA 218180, held by Torrent Pharmaceuticals. Venlafaxine Hydrochloride.
As of Nov 21, 2026, ANDA 218180 (Venlafaxine Hydrochloride), held by Torrent Pharmaceuticals, was first approved by FDA on Jan 28, 2025, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 28, 2025 | Original application | Approved | None posted |
| Venlafaxine HydrochlorideEQ 37.5MG BASE ยท tablet, extended release;oral | Venlafaxine Hydrochloride | Discontinued |
| Venlafaxine HydrochlorideEQ 75MG BASE ยท tablet, extended release;oral | Venlafaxine Hydrochloride | Discontinued |
| Venlafaxine HydrochlorideEQ 150MG BASE ยท tablet, extended release;oral | Venlafaxine Hydrochloride | Discontinued |
| Venlafaxine HydrochlorideEQ 225MG BASE ยท tablet, extended release;oral | Venlafaxine Hydrochloride | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters